Expression and phosphorylation of stathmin correlate with cell migration in esophageal squamous cell carcinoma

Liu,Fei; Sun,Yu-Lin; Xu,Yang; Liu,Fang; Wang,Li-Shun; Zhao,Xiao-Hang

doi:10.3892/or.2012.2157

Expression and phosphorylation of stathmin correlate with cell migration in esophageal squamous cell carcinoma

Authors:
- Fei Liu
- Yu-Lin Sun
- Yang Xu
- Fang Liu
- Li-Shun Wang
- Xiao-Hang Zhao
View Affiliations

Affiliations: State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China, Βeijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, P.R. China, Center of Basic Medical Sciences, Navy General Hospital, Beijing 100048, P.R. China
Published online on: November 28, 2012 https://doi.org/10.3892/or.2012.2157
Pages: 419-424
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Microtubules play extensive roles in cellular processes, including cell motility. Stathmin is an important protein which destabilizes microtubules. The essential function of stathmin is closely associated with its phosphorylation status. Stathmin is overexpressed in many human cancers and has a significant relationship with clinical characteristics such as grade, tumor size and prognosis. We demonstrated that stathmin was overexpressed in ESCC tissues using both 2-DE and immunohistochemistry analysis. In addition, overexpression of stathmin was significantly correlated with histological grade in ESCC. However, no correlation was found with age, gender and lymph node metastasis. Knockdown of stathmin with siRNA impaired cell migration in KYSE30 and KYSE410 cells. When EC0156 cells were treated with paclitaxel, stathmin was stably phosphorylated and migration was impaired. These observations suggest that stathmin may have a more important function in ESCC development and migration. The present study provides further understanding of the importance of stathmin in ESCC therapy or diagnosis.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2	Lin DC, Du XL and Wang MR: Protein alterations in ESCC and clinical implications: a review. Dis Esophagus. 22:9–20. 2009. View Article : Google Scholar : PubMed/NCBI
3	Steinmetz MO: Structure and thermodynamics of the tubulin-stathmin interaction. J Struct Biol. 158:137–147. 2007. View Article : Google Scholar : PubMed/NCBI
4	Belmont LD and Mitchison TJ: Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell. 84:623–631. 1996. View Article : Google Scholar : PubMed/NCBI
5	Cassimeris L: The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol. 14:18–24. 2002. View Article : Google Scholar : PubMed/NCBI
6	Manna T, Thrower DA, Honnappa S, Steinmetz MO and Wilson L: Regulation of microtubule dynamic instability in vitro by differentially phosphorylated stathmin. J Biol Chem. 284:15640–15649. 2009. View Article : Google Scholar : PubMed/NCBI
7	Marklund U, Larsson N, Gradin HM, Brattsand G and Gullberg M: Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J. 15:5290–5298. 1996.PubMed/NCBI
8	Amayed P, Pantaloni D and Carlier MF: The effect of stathmin phosphorylation on microtubule assembly depends on tubulin critical concentration. J Biol Chem. 277:22718–22724. 2002. View Article : Google Scholar : PubMed/NCBI
9	Niethammer P, Bastiaens P and Karsenti E: Stathmin-tubulin interaction gradients in motile and mitotic cells. Science. 303:1862–1866. 2004. View Article : Google Scholar : PubMed/NCBI
10	Liu Z, Lu H, Shi H, et al: PUMA overexpression induces reactive oxygen species generation and proteasome-mediated stathmin degradation in colorectal cancer cells. Cancer Res. 65:1647–1654. 2005. View Article : Google Scholar
11	Kim JY, Harvard C, You L, et al: Stathmin is overexpressed in malignant mesothelioma. Anticancer Res. 27:39–44. 2007.PubMed/NCBI
12	Nakashima D, Uzawa K, Kasamatsu A, et al: Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. Int J Cancer. 118:704–713. 2006. View Article : Google Scholar : PubMed/NCBI
13	Wang F, Wang LX, He W, Zhu LN, Zhao PR and Fan QX: Expression of stathmin in esophageal squamous cell carcinoma and its biological significance. Nan Fang Yi Ke Da Xue Xue Bao. 30:1552–1557. 2010.(In Chinese).
14	Wang X, Fan QX, Zhao PR and Wang F: Expression and significance of stathmin in esophageal squamous cell carcinoma. J Basic Clin Oncol. 120:372–374. 2007.
15	Wang F, Wang LX, Fan QX and Zhao PR: Inhibitory effects of ASODN of stathmin gene on cultured Eca109 cell lines. J Zhengzhou University (Medical Sciences). 43:414–418. 2008.
16	Wang Q, Xu Y, Zhao X, et al: A facile one-step in situ functionalization of quantum dots with preserved photoluminescence for bioconjugation. J Am Chem Soc. 129:6380–6381. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kouzu Y, Uzawa K, Koike H, et al: Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer. 94:717–723. 2006.PubMed/NCBI
18	Trovik J, Wik E, Stefansson IM, et al: Stathmin overexpression identifies high risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res. 17:3368–3377. 2011. View Article : Google Scholar : PubMed/NCBI
19	Salvesen HB, Das S and Akslen LA: Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res. 6:153–159. 2000.PubMed/NCBI
20	Sun Y, Mi W, Cai J, et al: Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res. 7:3847–3859. 2008. View Article : Google Scholar
21	Rana S, Maples PB, Senzer N and Nemunaitis J: Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther. 8:1461–1470. 2008. View Article : Google Scholar : PubMed/NCBI
22	Liu F, Liu F, Sun YL and Zhao XH: Significance of STMN1 expression in esophageal squamous cell carcinoma. World Chin J Digestol. 18:1306–1312. 2010.
23	Sadow PM, Rumilla KM, Erickson LA and Lloyd RV: Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors. Endocr Pathol. 19:97–103. 2008. View Article : Google Scholar : PubMed/NCBI
24	Bjorklund P, Cupisti K, Fryknas M, et al: Stathmin as a marker for malignancy in pheochromocytomas. Exp Clin Endocrinol Diabetes. 118:27–30. 2010. View Article : Google Scholar : PubMed/NCBI
25	Xi W, Rui W, Fang L, Ke D, Ping G and Hui-Zhong Z: Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol. 135:837–846. 2009. View Article : Google Scholar : PubMed/NCBI
26	Cheng AL, Huang WG, Chen ZC, et al: Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res. 14:435–445. 2008. View Article : Google Scholar : PubMed/NCBI
27	Jeon TY, Han ME, Lee YW, et al: Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer. 102:710–718. 2010. View Article : Google Scholar : PubMed/NCBI
28	Yuan RH, Jeng YM, Chen HL, et al: Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 209:549–558. 2006. View Article : Google Scholar
29	Gan L, Guo K, Li Y, et al: Up-regulated expression of stathmin may be associated with hepatocarcinogenesis. Oncol Rep. 23:1037–1043. 2010.PubMed/NCBI
30	Kuo MF, Wang HS, Kuo QT, et al: High expression of stathmin protein predicts a fulminant course in medulloblastoma. J Neurosurg Pediatr. 4:74–80. 2009. View Article : Google Scholar : PubMed/NCBI
31	Lin WC, Chen SC, Hu FC, et al: Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology. 74:1264–1269. 2009. View Article : Google Scholar : PubMed/NCBI
32	Su D, Smith SM, Preti M, et al: Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer. 115:2453–2463. 2009. View Article : Google Scholar : PubMed/NCBI
33	Takahashi K and Suzuki K: Membrane transport of WAVE2 and lamellipodia formation require Pak1 that mediates phosphorylation and recruitment of stathmin/Op18 to Pak1-WAVE2-kinesin complex. Cell Signal. 21:695–703. 2009. View Article : Google Scholar : PubMed/NCBI
34	Ravelli RB, Gigant B, Curmi PA, et al: Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 428:198–202. 2004. View Article : Google Scholar : PubMed/NCBI
35	Di Paolo G, Antonsson B, Kassel D, Riederer BM and Grenningloh G: Phosphorylation regulates the microtubule-destabilizing activity of stathmin and its interaction with tubulin. FEBS Lett. 416:149–152. 1997.PubMed/NCBI
36	Moreno FJ and Avila J: Phosphorylation of stathmin modulates its function as a microtubule depolymerizing factor. Mol Cell Biochem. 183:201–209. 1998. View Article : Google Scholar : PubMed/NCBI
37	Antonsson B, Kassel DB, Ruchti E and Grenningloh G: Differences in phosphorylation of human and chicken stathmin by MAP kinase. J Cell Biochem. 80:346–352. 2001. View Article : Google Scholar : PubMed/NCBI
38	Gadea BB and Ruderman JV: Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/Stathmin. Proc Natl Acad Sci USA. 103:4493–4498. 2006. View Article : Google Scholar : PubMed/NCBI
39	Chen PW, Lin SJ, Tsai SC, et al: Regulation of microtubule dynamics through phosphorylation on stathmin by Epstein-Barr virus kinase BGLF4. J Biol Chem. 285:10053–10063. 2010. View Article : Google Scholar : PubMed/NCBI
40	Andersen SS: Spindle assembly and the art of regulating microtubule dynamics by MAPs and Stathmin/Op18. Trends Cell Biol. 10:261–267. 2000. View Article : Google Scholar : PubMed/NCBI
41	Mistry SJ, Bank A and Atweh GF: Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure. Mol Cancer Res. 5:773–782. 2007. View Article : Google Scholar : PubMed/NCBI
42	Honore S, Pasquier E and Braguer D: Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci. 62:3039–3056. 2005. View Article : Google Scholar : PubMed/NCBI
43	Cernuda-Morollon E, Millan J, Shipman M, Marelli-Berg FM and Ridley AJ: Rac activation by the T-cell receptor inhibits T cell migration. PLoS One. 5:e123932010. View Article : Google Scholar : PubMed/NCBI
44	Belletti B, Nicoloso MS, Schiappacassi M, et al: Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell. 19:2003–2013. 2008. View Article : Google Scholar : PubMed/NCBI